SAB Biotherapeutics (SABS) Operating Income (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Operating Income came in at -$20.0 million in Q1 2026, down 85.64% YoY from -$139.3 million in Q1 2025, and down 26.81% on a QoQ basis from -$15.8 million in Q4 2025.
SAB Biotherapeutics (SABS) Operating Income (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Operating Income data on file, last reported at -$20.0 million in Q1 2026.
- Quarterly Operating Income fell 85.64% year-over-year to -$20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.2 million (down 37.56% YoY) and the FY2025 annual result came in at -$49.0 million, down 14.08% from the prior year.
- Operating Income fell to -$20.0 million in Q1 2026, from -$15.8 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$5.3 million in Q3 2023 to a low of -$20.0 million in Q1 2026.
- A 5-year average of -$10.5 million and a median of -$10.0 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 924.07% — and 2024, when it soared 46.97%.
- Tracing SABS's Operating Income over 5 years: stood at -$7.9 million in 2022, then sank by 140.12% to -$18.9 million in 2023, then soared by 46.97% to -$10.0 million in 2024, then tumbled by 57.56% to -$15.8 million in 2025, then slipped by 26.81% to -$20.0 million in 2026.
- The last three Operating Income figures came in at -$20.0 million (Q1 2026), -$15.8 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | -23.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.38 Mn |
| Mar 31, 2026 | -20.00 Mn |
| Dec 31, 2025 | -15.77 Mn |
| Sep 30, 2025 | -12.68 Mn |
| Jun 30, 2025 | -9.73 Mn |
| Mar 31, 2025 | -10.77 Mn |
| Dec 31, 2024 | -10.01 Mn |
| Sep 30, 2024 | -11.31 Mn |
| Jun 30, 2024 | -10.20 Mn |
| Mar 31, 2024 | -11.39 Mn |
| Dec 31, 2023 | -18.87 Mn |
| Sep 30, 2023 | -5.32 Mn |
| Jun 30, 2023 | -6.48 Mn |
| Mar 31, 2023 | -7.40 Mn |
| Dec 31, 2022 | -7.86 Mn |
| Sep 30, 2022 | -7.81 Mn |
| Jun 30, 2022 | -6.54 Mn |
| Mar 31, 2022 | -6.71 Mn |
| Dec 31, 2021 | -7.34 Mn |
| Sep 30, 2021 | -3.99 Mn |